IFNA1 and neoplasm: The clinical use of certain cytokines (i.e., IFN-α and IL-2), the subsequent identification of the first set of human tumor antigens, the progress on cancer vaccines and in the development of protocols based on adoptive cell therapy have all represented important milestones in the field of cancer immunotherapy.